Therapy News and Research

RSS

Los Alamos National Laboratory identifies 'Top 10 Laboratory science stories of 2009'

Los Alamos National Laboratory (www.lanl.gov) has identified the Top 10 Laboratory science stories of 2009 based on global viewership of online media content and major programmatic milestones.

9 Jan 2010

Recent releases in Global Health

A Lancet Comment examines the "grossly insufficient" progress towards meeting the Millennium Development Goal (MDG) of reducing under-5 child mortality. "Accelerated progress can be achieved, even in the poorest environments, through: integrated, evidence-driven, and community-based programmes that focus on addressing the major causes of death, including pneumonia, diarrhoea, newborn disorders, malaria, HIV, and undernutrition; reaching the unreached with a basic package of interventions at large scale and achieving coverage with equity; and using data for action and advocacy," the comment concludes (You et al., 1/9).

9 Jan 2010

Scientific societies to hold Experimental Biology 2010 meeting

Six scientific societies announced they will hold their annual meeting, Experimental Biology (EB 2010; www.experimentalbiology.org), April 24-28, 2010 in Anaheim, CA. The societies are the American Association of Anatomists (AAA), American Physiological Society (APS), American Society for Biochemistry and Molecular Biology (ASBMB), American Society for Investigative Pathology (ASIP), American Society for Nutrition (ASN) and American Society for Pharmacology and Experimental Therapeutics (ASPET).

9 Jan 2010

ChromoCure announces interim stockholder guidance on upcoming events

ChromoCure, Inc. announced today interim stockholder guidance on upcoming events. Full details on the below items will be released in the coming days.

9 Jan 2010

AIIRA/CCB drug combination provides superior safety and efficacy compared to other fixed-dose combinations

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a hypertension drug that requires less-frequent dosing than Novartis's Diovan/Tareg (valsartan) would earn 30 percent patient share according to surveyed U.S. cardiologists

9 Jan 2010

TRIA Beauty receives OTC clearance from FDA for hand-held blue light device

TRIA Beauty, the leader in light-based therapeutic beauty devices, today announced it received over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a hand-held blue light device designed for at-home use.

9 Jan 2010

Biomarker may enable personalized GVHD treatment for bone marrow transplant patients

University of Michigan researchers have identified the first biomarker of graft-versus-host disease of the skin. The discovery makes possible a simple blood test that should solve a treatment dilemma facing doctors with patients who frequently develop rashes after bone marrow transplants.

9 Jan 2010

FDA yet to review MannKind’s NDA for insulin therapy

MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind’s new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.

9 Jan 2010

New stem cell therapies to feature at 5th Annual Stem Cell Summit in NYC

Six new stem cell therapies, all forecast to reach physicians in 2010, will be featured at the 5th Annual Stem Cell Summit on February 16 in New York City. These new therapies include allograft products, innovative forms of autologous stem cell technologies, and at least one FDA-approved stem cell drug. New studies showing rehydration of the disc nucleus, regeneration of new heart muscle and others are also on the agenda.

9 Jan 2010

ChiroCode Institute and Avazzia jointly promote advanced technology devices

ChiroCode Institute and Avazzia will jointly promote advanced technology devices that help chiropractors and other caregivers manage their patients' chronic pain. The Avazzia BEST Pro Sport device combines microcurrent transcutaneous stimulation with somatic bio-feedback to provide improved results while making obsolete existing TENS devices.

9 Jan 2010

Savient Pharmaceuticals announces filing of KRYSTEXXA BLA resubmission on track

Savient Pharmaceuticals, Inc. provided an update on its activities directed toward the resubmission of its Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy and reaffirmed its belief that it continues to be on track for the filing of the BLA resubmission for KRYSTEXXA in the first quarter of 2010.

9 Jan 2010

LehmanMillet honored with four prestigious industry awards

HealthSTAR's LehmanMillet, the leading agency devoted to working with health care companies changing standards of care, today announced it has won four prestigious industry awards: an MM&M (Medical Marketing & Media Magazine) Gold Award for work done on behalf of Abbott Nutrition; a First Place DxMA (Diagnostic Marketing Association) award for work done on behalf of Abbott Diagnostics; a First Place DxMA Award for work done on behalf of BRAHMS USA; and a PM360 Pharma Choice Bronze Award.

9 Jan 2010

Neurosurgeons perform world's first operation on 'habenula' to treat depression

A team of neurosurgeons at Heidelberg University Hospital and psychiatrists at the Central Institute of Mental Health, Mannheim have for the first time successfully treated a patient suffering from severe depression by stimulating the habenula, a tiny nerve structure in the brain.

8 Jan 2010

Genentech's ACTEMRA approved to treat RA

Genentech, Inc., a wholly owned member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved ACTEMRA® (tocilizumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

8 Jan 2010

Sybaritic to stop production and distribution of medical devices

Sybaritic Inc., a medical device maker, has agreed to stop producing and distributing its medical products used in laser surgery, dermatology, and spa treatments until it is in compliance with FDA quality standards.

8 Jan 2010

Specialized software provides 3D images of individual patients' livers

Odysseus has developed systems to construct 3D images of individual patients' livers, with their tumours or other pathologies, from MRI or CT-scans. The reconstructions can be transmitted to external experts in any location, for consultation in real time just before surgery.

8 Jan 2010

Aneeve Nanotechnologies selected to work in the UCLA on-campus Technology Incubator Program

Aneeve Nanotechnologies LLC has been selected to work in the UCLA on-campus Technology Incubator Program at the California NanoSystems Institute. The startup company will conduct early-stage research for the development of a novel hormone sensor/meter for biomedical applications in the areas of infertility and menopause.

8 Jan 2010

Critically ill children with flu-like symptoms should be treated preemptively with antiviral medications

Lessons learned from the first 13 children at Johns Hopkins Children's Center to become critically ill from the H1N1 virus show that although all patients survived, serious complications developed quickly, unpredictably, with great variations from patient to patient and with serious need for vigilant monitoring and quick treatment adjustments.

8 Jan 2010

Chinese researchers become the world's fifth most prolific contributors to regenerative medicine

Chinese researchers have become the world's fifth most prolific contributors to peer-reviewed scientific literature on clock-reversing regenerative medicine even as a skeptical international research community condemns the practice of Chinese clinics administering unproven stem cell therapies to domestic and foreign patients.

8 Jan 2010

3Sbio submits registrational clinical trial application for Feraheme injection

3SBio Inc., a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a registrational clinical trial to the Chinese State Food and Drug Administration ("SFDA") for Feraheme (ferumoxytol) Injection for intravenous use.

8 Jan 2010